|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 275, Issue 42, 32444-32451, October 20, 2000
From the
Received for publication, May 22, 2000, and in revised form, July 7, 2000
Pex5p is the receptor for the vast majority of
peroxisomal matrix proteins. Here, we show that about 15% of rat liver
Pex5p is found in the peroxisomal fraction representing 0.06% of total peroxisomal protein. This population of Pex5p displays all the characteristics of an intrinsic membrane protein. Protease protection assays indicate that this pool of Pex5p has domains exposed on both
sides of the peroxisomal membrane. The strong interaction of Pex5p with
the membrane of the organelle is not affected by mild protease
treatment of intact organelles, conditions that result in the partial
degradation of Pex13p. Cytosolic Pex5p is a monomeric protein. In
contrast, virtually all peroxisomal Pex5p was found to be part of a
stable 250-kDa protein assembly. This complex was isolated and shown to
comprise just two subunits, Pex5p and Pex14p.
In the last years, great advances have been made in the
characterization of the biogenesis mechanism of peroxisomes (reviewed in Refs. 1 and 2). Peroxisomal matrix proteins are made on free
ribosomes and post-translationally imported into the organelle (3). At
least two types of peroxisome-targeting sequences
(PTSs)1 have been defined for
this class of proteins. The majority of peroxisomal matrix proteins
contain the so-called PTS1, a C-terminal tri-peptide with the sequence
SKL (and variants) (2, 4); a minor fraction of matrix proteins are
targeted to the organelle via PTS2, a N-terminal nona-peptide with the
sequence (R/K)(L/V/I)X5(H/Q)(L/A) (2, 5).
Proteins capable of recognizing these two signal sequences have been
identified and characterized in several organisms. These are Pex5p
(6-9) and Pex7p (10-12), the receptors for PTS1- and PTS2-containing
proteins, respectively.
Subcellular fractionation studies revealed that although the majority
of Pex5p behaves as a soluble cytosolic protein, a small fraction of
this peroxin is consistently found in the peroxisomal fraction
(13-15). In mammals and yeast, the peroxisomal pool of Pex5p is
strongly attached to the membrane of the organelle (8, 9, 16), an
interaction that most likely is mediated by proteinaceous components.
In support of this view, several peroxisomal intrinsic membrane
proteins capable of interacting directly with the PTS1 receptor have
been identified (see below). These observations provide the basis for
the currently accepted model of peroxisomal matrix protein import (see
Refs. 1 and 2). According to this model, Pex5p interacts with
PTS1-containing proteins in the cytosol, binds to a docking factor(s)
at the surface of the peroxisomal membrane, releases its cargo to some
peroxisomal membrane component, and is shuttled back to the cytosol. An
extended version of this model, in which the Pex5p-ligand complex is
completely translocated across the peroxisomal membrane, has also been
proposed (15).
Particular attention has been given to the identification and
characterization of proteins that are capable of interacting with
Pex5p. By using the two-hybrid system, in vitro binding
assays and co-immunoprecipitation analysis, direct interactions of
Pex5p with Pex8p (17), Pex12p (18), Pex13p (13, 14, 19), and Pex14p
(20, 21) have been demonstrated. It was proposed by several authors
that Pex13p and Pex14p represent the peroxisomal docking factors for
Pex5p (13, 14, 19-21), although recently, some doubts were raised
regarding the role of Pex14p in this process (Ref. 22 and see under
"Discussion"). Despite all these data, not much is known about the
architecture of the peroxisomal import machinery. For instance, it is
still not clear whether some of these peroxins are subunits of stable
protein complexes or if all the interactions that have been
characterized so far reflect the existence of transient events in vivo.
If there are stable peroxin complexes on the peroxisomal membrane, then
a strategy involving the isolation and characterization of these
complexes could provide important structural data regarding the
peroxisomal import machinery. It is obvious that some technical limitations may arise when applying such strategy; peroxins are low
abundance proteins and some are intrinsic membrane proteins. Nevertheless, we have recently observed that chemical amounts of rat
liver Pex3p can be easily obtained under denaturing conditions (23). In
this work, we extend this observation to rat liver Pex5p. This time, a
purification protocol using native conditions was used. We show that
peroxisome-associated Pex5p is part of a stable protein complex
comprising Pex14p. Other striking observations regarding the
peroxisomal pool of Pex5p are presented.
Subcellular Fractionation and Protease Protection
Assays--
Isolation of peroxisomes and preparation of a cytosolic
fraction from rat liver by differential centrifugation were performed as described (24) with minor modifications (23). The peroxisomes used
in this work were 92-94% pure having minor contaminations with
endoplasmic reticulum (4%) and mitochondria (2%), as judged by the
relative specific activities of marker enzymes (calculated according to
Ref. 24). Alkaline carbonate extraction of peroxisomes (25) and
alkaline sucrose gradient floatation of membranes (23) were performed
exactly as described. Extraction of peroxisomes using solutions of low
or high ionic strength was performed as follows: freshly isolated rat
liver peroxisomes at 1 mg/ml in SIE buffer (0.25 M sucrose,
5 mM imidazole HCl, pH 7.2, 1 mM EDTA-NaOH, pH
7.2) or SIE buffer containing 0.5 M NaCl were sonicated
three times for 10 s (with a 30-s interval on ice) using a Heat
Systems/Ultrasonics sonicator (model W-375) equipped with a microtip
and set to 50% duty cycle, output 2. After sonication, the samples
were halved. One-half was kept on ice as a control, and the other was
separated into membrane and soluble fractions by centrifugation for
1 h at 135,000 × g. Protein in the samples was
precipitated with 10% (w/v) trichloroacetic acid (added from a 100%
(w/v) stock solution). After 30 min on ice, the precipitated protein
was pelleted (15 min at 15,000 × g), washed with
acetone, solubilized in Laemmli sample buffer (26) (15 min at 80 °C
with vigorous agitation), and separated by SDS-PAGE.
For the protease protection assays, freshly isolated rat liver
peroxisomes (at 2 mg/ml, unless otherwise indicated) in SIE buffer were
incubated on ice in the presence of the protease (freshly dissolved in
SIE buffer) for 30 min. Where indicated, Triton X-100 was added to a
final concentration of 0.1% (w/v) before adding the protease. Protease
treatment of sonicated organelles was performed as follows: immediately
after addition of the protease, organelles were sonicated as described
above and incubated on ice for 30 min. Proteases were inactivated by
incubation on ice for 2 min with 2 mM phenylmethanesulfonyl
fluoride (added from a 0.2 M stock solution in ethanol).
The proteins were precipitated immediately with trichloroacetic acid
and processed for SDS-PAGE as described above.
Partial Purification of Peroxisomal Pex5p--
In a typical
experiment, the purification procedure was started with a pellet of 30 mg of purified peroxisomes. The organelles were solubilized in 4.8 ml
of buffer A (20 mM Tris-HCl, pH 8.0, 0.5% (w/v) sodium
deoxycholate, 1% (w/v) Nonidet P-40, 150 mM NaCl, 1 mM EDTA, 50 µg/ml 4-(2-aminoethyl)benzenesulfonyl
fluoride, 5 µg/ml pepstatin A, 2 µg/ml
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane, 40 µg/ml bestatin, 5 µg/ml leupeptin, and 2 µg/ml aprotinin) for 30 min at 4 °C and subjected to ultracentrifugation at 135,000 × g for 30 min at 4 °C in the 65.13 angular rotor
(Sorvall). The insoluble material was discarded. To the supernatant,
50% (w/v) polyethylene glycol 4000 in buffer A was added to achieve a
final concentration of 10% (w/v). After incubation on ice for 15 min, the sample was centrifuged at 15,000 × g for 15 min.
To the resultant supernatant, 50% (w/v) polyethylene glycol 4000 in
buffer A was added to give a final concentration of 15% (w/v). This
sample was incubated on ice for 15 min and centrifuged at 15,000 × g for 15 min. The pellet obtained (enriched in Pex5p) was
solubilized in 600 µl of buffer B (containing 44 mM
Bis-Tris-HCl, pH 7.0, 0.75 M 6-aminocaproic acid, 1% (w/v)
Nonidet P-40, 0.5% (w/v) sodium deoxycholate, 50 µg/ml
4-(2-aminoethyl)benzenesulfonyl fluoride, 5 µg/ml pepstatin A, 2 µg/ml
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane, 40 µg/ml bestatin, 5 µg/ml leupeptin, and 2 µg/ml aprotinin) and centrifuged at 15,000 × g for 15 min. The resultant
supernatant was mixed with 106 µl of saturated ammonium sulfate
solution (pH 7.0 with NH4OH), incubated on ice for 15 min,
and centrifuged at 15,000 × g for 15 min. To the
supernatant obtained, 94 µl of saturated ammonium sulfate solution
was added. After incubation on ice for 15 min, the sample was
centrifuged at 15,000 × g for 15 min. At this step,
the precipitated protein was washed three times with 1 ml of 25%
saturated ammonium sulfate solution, centrifuging (15,000 × g for 5 min at 4 °C) between each wash. This pellet was
then solubilized in 600 µl of buffer A and applied to the top of a
discontinuous sucrose gradient (2.7 ml of 7.5%, 2.5 ml of 10%, 2.1 ml
of 15.5%, 1.7 ml of 21%, and 1.5 ml of 25% (w/v) sucrose in a buffer
containing 50 mM Tris acetic acid, pH 8.0, 1 mM
EDTA, and 0.1% Nonidet P-40). After centrifugation at 165,000 × g for 16 h at 4 °C in a TST 41.14 swing-out rotor
(Sorvall), 13 fractions of 0.85 ml were collected from the bottom of
the tube and analyzed by Western blotting using the anti-Pex5p
antibody. The Pex5p-enriched fractions (fractions 9-12) were pooled.
Fifty µl (bed volume) of DEAE-Sepharose CL-6B (Amersham Pharmacia
Biotech) pre-equilibrated in buffer C (20 mM Tris-HCl, pH
8.0, 10% (v/v) glycerol, and 0.5% (w/v) Nonidet P-40) containing 25 mM NaCl, were added to this fraction. After incubation of
the suspension for 2 h at 4 °C with occasional shaking, the
DEAE-Sepharose beads were washed with 600 µl of buffer C containing
25 mM NaCl. The resin was sequentially washed with 200 µl
of 100, 150, 350, and 500 mM NaCl in buffer C. Pex5p was
recovered in the 350 mM NaCl wash step as revealed by
immunoblot analysis using the anti-Pex5p antibody. In a typical
experiment, 10 µg of this Pex5p-enriched material were obtained by
this procedure.
Antibodies--
To raise an antibody against human Pex12p, a
cDNA encoding amino acids 1-359 was amplified from human
skin fibroblasts total RNA by reverse transcription-PCR using the
primers 5'-gcggaattcacgcaggaaactatggctgagc-3' and
5'-ggcctgcagagacatgattccctttcagttctcagg-3' designed according to
the published sequence (27). The 1.1-kilobase pair cDNA fragment was digested with the EcoRI and PstI restriction
enzymes and cloned into the pBluescript II KS vector (Stratagene).
After digestion of the recombinant plasmid with EcoRI and
NotI, the insert was cloned into the pGEX-5X-1 (Amersham
Pharmacia Biotech) expression vector. The human Pex12p fused to the
glutathione S-transferase (GST) was expressed in the XL1
strain of Escherichia coli and obtained as inclusion bodies.
These were isolated, and the fusion protein was purified by SDS-PAGE
and used to immunize rabbits (28).
The human Pex5p cDNA was amplified by reverse transcription-PCR
using the primers 5'-ccggtcgacatggcaatgcgggagctggtgga-3' and 5'-gcggtcgacctgtcactggggcaggccaaacatag-3' designed according to the
published sequence (8). This molecule was cloned into the pGEM®-T easy
vector according to the manufacturer's instructions (Promega). The
recombinant plasmid was digested with EcoRI and SalI, and the insert was cloned in pGEX-5X-1 and pMAL-c2
(New England Biolabs) expression vectors. The recombinant proteins containing amino acids 142-639 of Pex5p fused to GST or
maltose-binding protein were expressed in the XL1 strain of E. coli. The GST-Pex5p fusion protein was purified by SDS-PAGE and
used to immunize rabbits (28). Anti-Pex5p antiserum was immunopurified
using the GST-Pex5p fusion protein blotted onto nitrocellulose membrane
as described (28).
The preparation and characterization of the antibody directed to human
Pex13p were described previously (23). The anti-catalase antibody was
obtained from Research Diagnostics, Inc. A monoclonal antibody (clone
7H10-BD4) directed to the Miscellaneous--
Total RNA from human fibroblasts was isolated
using the High Pure RNA Isolation Kit (Roche Molecular Biochemicals).
The reverse transcription-PCR was done using the TitanTM
One Tube Reverse Transcription-PCR System essentially as described by
the manufacturer (Roche Molecular Biochemicals).
Proteins were measured by the Lowry method using bovine serum albumin
as standard, as described (30).
SDS-PAGE was performed in 1.0-mm-thick 10 or 12% polyacrylamide gels
using the Laemmli discontinuous buffer system (26). Silver staining of
polyacrylamide gels was performed as described (31).
Blue native-PAGE was carried out according to the method of Schagger
and von Jagow (32) with slight modifications. Protein samples
(~200 µg) were solubilized in 70 µl of buffer B (see
above). After a clarifying spin (15 min at 15,000 × g), 5 µl of 5% (w/v) Coomassie Blue G-250 in 0.5 M 6-aminocaproic acid was added to the sample before
electrophoresis. Samples containing high concentrations of salt were
first dialyzed against 50 ml of buffer B for 1 h, before addition
of 5% (w/v) Coomassie Blue G-250 in 0.5 M
6-aminocaproic acid. Samples were resolved on 5-13% polyacrylamide
gradient slab gels prepared according to Schagger and von Jagow (32)
but containing 0.1% (w/v) Nonidet P-40 in all solutions. The cathode
buffer contains 50 mM Tricine, 15 mM
Bis-Tris-HCl, pH 7.0, 0.05% (w/v) sodium deoxycholate, and 0.02%
(w/v) Coomassie Blue G-250. The anode buffer contains 50 mM Bis-Tris-HCl, pH 7.0. The gels were run for 16 h at
100 V (with constant voltage) at 4 °C. The second dimension was
performed on 10% SDS-polyacrylamide gels exactly as described
(32).
For the native sucrose gradient centrifugation analysis, protein
samples (usually 2 mg) were solubilized in 600 µl of buffer A (see
above) and loaded on the top of a discontinuous sucrose density
gradient as described above. Centrifugation was carried out at
165,000 × g for 16 h at 4 °C in a TST 41.14 rotor (Sorvall). Thirteen fractions of 0.85 ml were collected from the
bottom of the gradient, precipitated with trichloroacetic acid, and
analyzed by SDS-PAGE.
Western blotting onto nitrocellulose membranes (Schleicher & Schuell)
was performed according to the manufacturer's instructions.
Densitometric analysis of immunoblots was carried out using the LKB
BROMMA densitometer.
MALDI-MS of tryptic fragments of Coomassie Blue-stained protein bands
in SDS-polyacrylamide gels was performed by HHMI/Keck Biotechnology
Resource Laboratory (New Haven, CT).
A Considerable Fraction of Rat Liver Pex5p Is Peroxisome-associated
and Behaves as an Intrinsic Membrane Protein--
As a first step to
characterize rat liver Pex5p we have determined the percentage of this
protein that co-isolates with peroxisomes. For this purpose, highly
pure peroxisomes and total homogenate from rat liver were subjected to
Western blotting analysis using an antibody directed to human Pex5p
(see Fig. 1A). Densitometric analysis of this blot (data not shown), together with the fact that
peroxisomal protein corresponds to 2% of total rat liver protein (24),
allowed us to estimate that 15% of Pex5p is peroxisome-associated. In
a similar experiment, the amount of Pex5p in nanograms per microgram of
total peroxisomal protein was also estimated (see Fig. 1B).
A value of 0.6 ng of Pex5p per µg of total peroxisomal protein was
obtained. This should be regarded as a minimal value since rat Pex5p
may not be recognized by the anti-human Pex5p antibody as strongly as
the human recombinant Pex5p protein used in this experiment as a
standard.
Virtually all peroxisome-associated Pex5p behaves as an intrinsic
membrane protein. Indeed, this pool of Pex5p cannot be extracted from
the peroxisomal membrane either by sonication in low or high ionic
strength buffers or by incubation of peroxisomal membranes at alkaline
pH (see Fig. 2A). The
possibility that Pex5p per se is not soluble under the
conditions employed was still considered. However, this is clearly not
the case. When alkali-treated peroxisomes are subjected to alkaline
sucrose density floatation (23), both Pex5p and Pex12p (but not
catalase) are found on the top of the sucrose gradient (Fig.
2B), a characteristic of peroxisomal intrinsic membrane
proteins (23).
Finally, the behavior of peroxisome-associated Pex5p upon SDS-PAGE is
not changed by reduction of the protein sample with dithiothreitol
prior to electrophoresis (see Fig. 2C). Thus, the interaction of Pex5p with the peroxisomal membrane does not involve a
thiol-cleavable covalent bound to some intrinsic membrane protein of
this organelle.
Peroxisomal Pex5p Is a Transmembrane Protein--
As shown above,
peroxisome-associated Pex5p displays all the characteristics of a
typical intrinsic membrane protein. What is the topology of this
protein in the peroxisomal membrane? To address this question we have
performed a protease protection assay. For this purpose, freshly
isolated rat liver peroxisomes were treated with different amounts of
proteinase K. After inactivation of the protease, the protein was
precipitated with trichloroacetic acid and analyzed by Western blotting
using antibodies directed to Pex13p and Pex5p. Mammalian Pex13p is an
intrinsic membrane protein having at least its C-terminal SH3 domain
exposed to the cytosol (13, 14). In agreement with this model, when rat
peroxisomes are subjected to this proteolytic treatment, Pex13p is
readily accessible to the added protease (Fig.
3, lanes 2-5). However, a
fragment of this protein (a polypeptide of 28 kDa) remains
protease-protected even at the highest proteinase K concentration used
in this experiment. This domain becomes accessible only when the
peroxisomal membrane is disrupted by detergent (Fig. 3, lanes
7 and 8). It should be noted that under these
conditions the 28-kDa fragment of Pex13p is extremely sensitive to
proteinase K. Indeed, a protease concentration of only 0.1 µg/ml is
sufficient to degrade completely this peptide (data not shown) making
it a good marker to monitor the integrity of the peroxisomal
membrane.
When the behavior of rat Pex5p in this experiment is analyzed, a
strikingly similar result is found. A domain of approximately 2 kDa is
clipped from Pex5p when intact peroxisomes are subjected to the
protease treatment. Although this cleavage requires relatively high
proteinase K concentrations, it clearly occurs under conditions in
which the 28-kDa fragment of Pex13p is fully protected (see Fig. 3,
lanes 4 and 5). Thus, at least a short domain of
peroxisomal Pex5p is exposed into the cytosol. Finally, when the
peroxisomal matrix compartment is exposed to the protease by detergent
treatment of the organelles, Pex5p is completely degraded (Fig. 3,
lanes 7 and 8). Apparently, Pex5p is exposed on
both sides of the peroxisomal membrane.
When performing a protease protection assay it is generally assumed
that addition of a mild detergent (e.g. Triton X-100) just
solubilizes the membrane of the organelle thus exposing the lumenal
domains of the protein under study to the action of the protease used
in the assay. However, we have to consider that some protein complexes
may not resist this solubilization procedure in an intact form. Thus,
it would be possible that the partial protease resistance of Pex5p in
intact organelles is just the result of a shielding effect performed by
other protein(s) to which Pex5p binds on the surface of the peroxisome;
after addition of the detergent this protein complex would be destroyed
exposing Pex5p to the protease. In order to test this possibility
peroxisomes were subjected to a mild sonication treatment in the
presence of proteinase K. As shown above (see Fig. 2A)
sonication of peroxisomes is not sufficient to disrupt the interaction
of Pex5p with the peroxisomal membrane. When the peroxisomal matrix
compartment is exposed to the protease using this method, both Pex5p
and Pex13p are digested even at low proteinase K concentrations (Fig.
3, lanes 10 and 11). Thus, the observed partial
resistance to proteinase K of Pex5p in intact organelles is the result
of shielding by the peroxisomal membrane itself. Taken together, these
data indicate that rat peroxisomal Pex5p is a transmembrane protein.
Pex5p Remains Attached to the Peroxisomal Membrane after Mild
Protease Treatment of Intact Organelles--
As shown above, when
intact peroxisomes are subjected to protease treatment only a small
peptide of Pex5p is removed. This cleavage reaction is not very
efficient, requiring a relatively high proteinase K concentration.
Indeed, treatment of peroxisomes with low concentrations of this
protease (e.g. 1-5 µg/ml; see Fig. 3) results in no
cleavage of Pex5p. A similar result is obtained when trypsin is used in
these experiments; Pex5p remains uncleaved when intact organelles are
incubated with trypsin concentrations up to 50 µg/ml. Nevertheless,
under these conditions Pex13p is degraded to a faster migrating species
on SDS-PAGE (see below). Taking these data into consideration and the
fact that Pex13p has been shown to interact with Pex5p (13, 14, 19), we
have determined whether the cytosolic (protease-accessible) domains of
rat Pex13p are essential for the interaction of Pex5p with the
peroxisomal membrane. For this purpose, freshly isolated rat liver
peroxisomes were incubated in the presence of trypsin (50 µg/ml).
After inactivation of the protease, the organelles were subjected to
alkaline extraction in order to isolate intrinsic membrane proteins
(see "Experimental Procedures"). Equivalent amounts of membrane
(Fig. 4, lane 4) and soluble
proteins (Fig. 4, lane 3) were analyzed by Western blotting
using antibodies directed to Pex13p and Pex5p. As shown in Fig. 4,
Pex13p was cleaved to a 30-kDa fragment by the action of trypsin. This
fragment is still membrane-associated in agreement with its membrane
topology model. As expected, Pex5p was not digested under these
conditions. Most importantly, virtually all Pex5p remained resistant to
the alkaline extraction. Thus, these results strongly suggest that the
cytosolic (protease-accessible) domains of Pex13p are not necessary to
maintain Pex5p strongly attached to the peroxisomal membrane.
Peroxisomal Pex5p Is Part of a Stable Protein Complex--
Besides
recognizing PTS1-containing proteins en route to the
peroxisome, Pex5p is able to interact with several other components of
the import machinery of this organelle. Indeed, using the two-hybrid system, in vitro binding assays and co-immunoprecipitation
analysis, Pex5p has been shown to interact directly with Pex8p (in
Saccharomyces cerevisiae (17)), Pex12p (in human cells
(18)), Pex13p (in fungi and human (13, 14, 19)), and Pex14p (in mammals
and S. cerevisiae (20-22)). However, our knowledge about
the architecture of this machinery is still limited. For instance, is
still not clear whether all these peroxins are part of stable complexes or if they just interact in a transient way. We think that a strategy involving the isolation and polypeptide characterization of complex(es) containing Pex5p could provide some insights on this issue.
In order to test the feasibility of this approach, we have determined
the molecular mass of peroxisomal Pex5p under native conditions.
Considering that the interactions of Pex5p with all the other peroxins
mentioned above are thought to occur at the peroxisomal membrane level
(and not in the cytosol), we have included cytosolic Pex5p in this
analysis. For this purpose, peroxisomal and cytosolic proteins from rat
liver were resolved by blue-native gel electrophoresis (32) followed by
a second dimension on SDS-PAGE and Western blot analysis.
As shown in Fig. 5A cytosolic
Pex5p migrates with an apparent molecular mass of 70-90 kDa. The
migration of catalase present in this fraction (presumably released
into the cytosol during the isolation of peroxisomes) is also shown for
comparison. Catalase is a tetrameric protein of 240 kDa (33). In sharp
contrast with cytosolic Pex5p, peroxisomal Pex5p displays an apparent
molecular mass of about 250 kDa. Similar results were obtained when the molecular masses of both the cytosolic and peroxisomal Pex5p were estimated by sucrose gradient sedimentation analysis (see Fig. 5B), although the (unknown) contribution of detergents and
phospholipids to the size of the proteins under study was not
considered.
Thus, the data presented suggest that cytosolic Pex5p is a monomeric
protein under the experimental conditions used. In addition, we show
that peroxisomal Pex5p is present in the membrane of the organelle as a
high molecular mass complex. This complex, or at least a fraction of
it, is stable and displays a molecular mass of about 250 kDa.
Isolation of Peroxisomal Pex5p Under Native Conditions--
The
fact that a stable protein complex containing Pex5p can be detected
after detergent solubilization of peroxisomes encouraged us to isolate
chemical amounts of this complex. A very simple procedure was developed
for this purpose. It involves a polyethylene glycol precipitation, an
ammonium sulfate precipitation, a sucrose density gradient
centrifugation, and a DEAE-Sepharose adsorption step (see
"Experimental Procedures" for details). Densitometric analysis of
immunoblots containing equivalent amounts of these fractions using the
anti-Pex5p antibody indicates that 12% of the initial amount of Pex5p
was recovered in the last step (see Table
I). The polypeptide compositions of the
Pex5p-enriched fractions obtained in each step of the purification
scheme are shown in Fig. 6. Three protein
bands presenting apparent molecular masses of 90, 60, and 44 kDa are
clearly enriched after the last step of the purification protocol (Fig.
6, lane 6).
In order to provide unambiguous proof that a Pex5p-containing complex
was indeed isolated and also to identify the two proteins co-purifying
with Pex5p, all the three major protein bands present in the
Pex5p-enriched fraction (Fig. 6, lane 6) were subjected to
MALDI-MS (see "Experimental Procedures"). The results of this analysis (see Table II) show that the
90-kDa polypeptide corresponds to Pex5p, as expected. Twelve peptides
comprising 27% of the mouse Pex5p sequence ((34) the rat Pex5p
sequence is not yet available) and derived from the region encompassing
amino acid residues 84-626 of this peroxin were detected by this
analysis.
When the 60-kDa protein band was subjected to MALDI-MS, 16 peptides
covering 45% of the rat Pex14p sequence (35) were detected (see Table
II). These peptides are derived from the Pex14p region encompassing
amino acid residues 26-376 (the last residue of this protein).
Unexpectedly, the 44-kDa protein band also corresponds to Pex14p. In
this case, only 12 peptides comprising 36% of the rat Pex14p sequence
and derived from the region encompassing amino acids residues 26 to 291 were detected upon MALDI-MS. It is possible that this polypeptide
represents a truncated form of Pex14p probably lacking some (not more
than 84) C-terminal amino acid residues.
These data clearly demonstrate that a Pex5p-Pex14p complex was isolated
using the purification procedure described here. Is this protein
assembly the same 250-kDa Pex5p-containing complex detected by
immunoblot analysis after detergent solubilization of peroxisomes or
were some subunits of this complex lost during the purification
procedure? In order to answer this question, we have analyzed the
Pex5p-Pex14p-enriched fraction described above (see Fig. 6, lane
6) by blue-native gel electrophoresis followed by a second
dimension on SDS-PAGE. As shown in Fig.
7, Pex5p displays exactly the behavior
previously shown for peroxisome-associated Pex5p by Western blotting
analysis (compare with Fig. 5A). (It is interesting to note
that the high resolution provided by the blue-native gel
electrophoresis system allows a partial separation of Pex5p-Pex14p
complexes from Pex5p complexes containing the 44-kDa Pex14p fragment.)
Thus, no components of the 250-kDa Pex5p-containing complex were lost
during the purification procedure employed. This result also implies
that there is more than one copy of at least one of the subunits in
this Pex5p-Pex14p complex. Indeed, two-dimensional densitometric
analysis of the gel shown in Fig. 7 indicates a Pex5p:Pex14p:Pex14p
fragment molar ratio of 1:3.1:2.0 (conversion of the densitometric
signals into molar equivalents was performed using the theoretical
molecular masses of mouse Pex5p and rat Pex14p and considering that the
44-kDa protein corresponds to Pex14p lacking its 84 C-terminal amino
acid residues). Assuming that these proteins do not exhibit an unusual
staining behavior, then this stoichiometry would result in a complex
with a predicted molecular mass of 255 kDa, a value in close agreement
with the obtained experimentally.
In this work, a biochemical characterization of the
peroxisome-associated pool of rat liver Pex5p is presented. As
described previously (8), this form of the PTS1 receptor displays all the typical characteristics of an intrinsic membrane protein. Indeed,
all attempts to extract Pex5p from the peroxisomal membrane using a
variety of techniques intended to release peroxisomal soluble and
peripheral membrane proteins have failed; solubilization of this form
of Pex5p could be accomplished only when detergents were used. This
observation could imply that 1) either Pex5p is in direct contact with
the lipid bilayer of the peroxisomal membrane or 2) Pex5p is strongly
associated with some intrinsic protein(s) of the peroxisomal membrane.
(A combination of the two possibilities is also feasible.) Although
there is no formal proof to support either of these models, it is
generally believed that the strong interaction of the PTS1-receptor
with the peroxisomal membrane is mediated by proteinaceous components.
In support of this view, direct interactions of Pex5p with Pex12p (18),
Pex13p (13, 14, 19), and Pex14p (20, 21), three peroxisomal intrinsic membrane proteins, have been shown. However, considering the nature of
the techniques used in those studies, several aspects remain obscure;
how strong are these interactions in vivo? Are they dynamic or are they involved in the formation of stable protein complexes? The
data presented in this work provide some insights into these questions.
In order to gather some more information regarding the interaction of
this peroxin with the peroxisomal membrane, we have tried to define the
membrane topology of Pex5p. By using protease protection assays,
peroxisomal Pex5p was found to be exposed on both sides of the
membrane. Although this is the first time that such a membrane topology
is shown for the PTS1 receptor, it is possible that this is not a
characteristic unique to rat Pex5p. As noted by Terlecky et
al. (9), peroxisome-associated (alkaline-resistant) Pex5p from
Pichia pastoris is more susceptible to proteinase K when the
peroxisomal membrane is first disrupted by addition of Triton
X-100.
The identities of the Pex5p domains facing each side of the membrane
are not known at the present. This will require the production of
antibodies directed to different domains of this protein. Nevertheless, data concerning the topology of several Pex5p-binding peroxins and the
domains involved in these interactions are already available. These
data, together with the results presented here, can be used to infer
some structural properties of the rat peroxisome-associated Pex5p.
The first peroxisomal integral membrane protein to be identified as a
Pex5p-binding protein was Pex13p (13, 14, 19). This interaction
involves the C-terminal SH3 domain of Pex13p (13, 14, 19) and an
N-terminal domain of Pex5p (amino acid residues 100-213 in the
P. pastoris Pex5p (36)). The finding that the SH3 domain of
Pex13p faces the cytosol led to the proposal that this peroxin is the
docking protein for the PTS1 receptor (13, 14, 19). However, recent
studies in S. cerevisiae clearly show that the steady-state
levels of Pex5p present in a membrane-embedded complex comprising
Pex14p, Pex17p, and a recombinant version of Pex7p remain unchanged
after deletion of the gene encoding Pex13p (37). Furthermore, as shown
here, rat liver Pex5p remains attached to the peroxisomal membrane in
an alkaline-resistant manner when the cytosolic (protease accessible)
domains of Pex13p are proteolytically removed. These data do not
exclude the possibility that Pex13p is somehow involved in the
recruitment of Pex5p from the cytosol into the peroxisomal membrane or,
as has been suggested recently (36), in the release of Pex5p from the
peroxisomal membrane into the cytosol. However, it seems plausible that
once insertion into the peroxisomal membrane occurs, Pex5p no longer
depends on this interaction to remain strongly associated with the
membrane. Thus, the prediction that the N-terminal domain of the
peroxisomal Pex5p described here is exposed into the cytosol based on
its interaction with the SH3 domain of Pex13p is not necessarily correct.
Pex14p was the second peroxin to be identified as a Pex5p-binding
protein (20-22, 38). In human, this interaction involves the
N-terminal half of Pex5p and the first 78 N-terminal amino acid
residues of Pex14p (39). The interaction of Pex14p with the peroxisomal
membrane in yeast cells is still a matter of controversy (20, 38, 40).
However, clear results regarding the mammalian Pex14p topology have
been recently published (22). The data presented by Will et
al. (22) strongly suggest that the N-terminal domain of human
Pex14p is exposed into the lumen of the organelle. Based on this
finding, the authors speculated that this would imply that the PTS1
receptor is in the lumen of the peroxisome at some stage of the protein
import process, an hypothesis that would be in support of the
"extended shuttle model of peroxisomal protein import" (15). Our
results clearly indicate that there is no need to make this assumption.
The Pex5p-Pex14p interaction involves a Pex5p population that is still
exposed on the cytosolic face of the peroxisomal membrane. The Pex14p
membrane topology proposed by Will et al. (22) together with
our results have another important implication; the Pex14p-binding
domain of the Pex5p population described here is exposed into the lumen
of the organelle.
We have shown that the rat liver cytosolic Pex5p behaves as a monomeric
protein. In contrast, virtually all peroxisome-associated Pex5p was
found to be part of a 250-kDa protein assembly. Chemical amounts of
this complex were isolated and shown to consist of only two subunits,
Pex5p and Pex14p. The ratio of Pex5p:Pex14p in the isolated complex was
estimated to be 1:5. It is interesting to note that an almost similar
Pex14p binding stoichiometry was described for recombinant human Pex5p
(39). However, some doubts were raised by these authors concerning the
possibility that all Pex14p-binding sites in Pex5p are occupied
in vivo. Our data strongly suggest that, indeed, this is the
case. Schliebs et al. (39) also noted that recombinant Pex5p
is capable of forming homotetramers. In contrast, we found no evidence
for homotetramerization of Pex5p. It remains to be shown whether this
discrepancy results from the solubilization conditions used in our work
or if it reflects the high protein concentrations used in the
experiments performed with the recombinant protein.
One intriguing aspect of the data presented here concerns the
biochemical homogeneity of the peroxisomal pool of rat Pex5p. As far as
the detection limits of an immunoblot analysis allow us to infer,
virtually all Pex5p present in rat liver peroxisomes behaves as an
intrinsic membrane protein. This Pex5p population is inserted into the
peroxisomal membrane having domains facing the two sides of the
membrane. Finally, we provide data suggesting that all peroxisomal
Pex5p is part of a stable protein complex comprising Pex14p (a
hypothetical model regarding the Pex5p-Pex14p complex is presented in
Fig. 8). These are quite unusual
properties for a protein that presumably is in transit either to the
cytosol (as proposed by the cycling receptor theory) or even to the
peroxisomal matrix compartment (as proposed in the extended version of
the cycling receptor model). If these models turn out to be true, then
our results simply indicate that the disruption of the Pex5p-Pex14p interaction is a rate-limiting step in rat liver. However, considering the data presented here, the possibility that this peroxisomal Pex5p
pool may represent a resident population of molecules should still be
considered. In this context, it is important to consider that
peroxisomal (alkaline-resistant) Pex5p from P. pastoris is capable of interacting with a PTS1-containing peptide (9), suggesting
that this membrane-embedded form of the PTS1-receptor may, indeed,
function as such in vivo.
*
This work was supported in part by Ministério da
Ciência e Tecnologia, Portugal, Grant PRAXIS XXI
2/2.1/SAU/1345/95.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
Supported by Ministério da Ciência e Tecnologia, Portugal.
**
To whom correspondence should be addressed: IBMC-UP, Rua do Campo
Alegre 823, 4150-180 Porto, Portugal. Tel.: 351-226074900; Fax:
351-226092404; E-mail: jazevedo@ibmc.up.pt.
Published, JBC Papers in Press, July 10, 2000, DOI 10.1074/jbc.M004366200
The abbreviations used are:
PTS, peroxisomal
targeting sequence;
PAGE, polyacrylamide gel electrophoresis;
PCR, polymerase chain reaction;
GST, glutathione S-transferase;
MALDI-MS, matrix-assisted laser desorption ionization-mass spectrometry;
Bis-Tris, 2-[bis(2- hydroxyethyl)amino]-2-(hydroxymethyl)propane-1,3-diol;
Tricine, N-[2- hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||